Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Bedwetting Knowledge Centre

Bedwetting, or nocturnal enuresis is defined as intermittent incontinence while sleeping. Applicable to children ≥ 5 years old, wetting episodes of any type that occur in discrete amounts are indicative to nocturnal enuresis.1,2

Due to variations in comorbidity, treatment response and pathogenesis, nocturnal enuresis can be divided into two subgroups – monosymptomatic nocturnal enuresis (MNE) and non-monosymptomatic nocturnal enuresis (NMNE).1,3 Absence of lower urinary tract symptoms or a history of bladder dysfunction is characteristic of MNE, while NMNE is defined as nocturnal enuresis accompanied by daytime urinary symptoms.

Nocturnal enuresis can have a profound impact on the child and their family, lowering a child’s self image, causing behavioural problems and affecting school performance. However, successful treatment improves the mental health of the child and brings practical relief to the family.

Latest News

FDA Advisory Committee rejects MoxDuo for Moderate to Severe Pain- QRxPharma

24-Apr-2014

QRxPharma announced that the FDA ...

NICE rejects Kadcyla for HER-2 positive Breast Cancer- Roche

24-Apr-2014

The The National Institute for ...

FDA approves Somatom Force CT Imaging system-Siemens

24-Apr-2014

The FDA has cleared the Somatom Force ...

Phase III trials success for tofacitinib in Plaque Psoriasis- Pfizer

23-Apr-2014

Pfizer Inc. announced top-line ...

ABT 450/r, ABT 267, ABT 333 combination submitted to FDA for Hepatitis C-AbbVie

23-Apr-2014

AbbVie has submitted a New Drug ...

FDA approves Cyramza for Gastric Cancer-Eli Lilly

23-Apr-2014

The FDA has approved Cyramza ...

Phase III trial shows Zonegran for Epilepsy well tolerated in young patients-Eisai

23-Apr-2014

Zonegran (zonisamide), from Eisai, is ...

Recent Updates

Drugs

Clinical Guidelines

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

Guidelines for Liver Transplantation for Patients with Non-Alcoholic Steatohepatitis

Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas

Borderline personality disorder: treatment and management

Medical Journals

Using Parent Questionnaires to Assess Neurodevelopment in Former Preterm Infants: A Validation Study

Variance of melatonin and cortisol rhythm in patients with allergic rhinitis

Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease

Long-term effect of persistent smoking on the prognosis of Chinese male patients after percutaneous coronary intervention with drug-eluting stent implantation

epgonline.org Social